An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients With Treatment-Resistant Bipolar Disorder: Response to Letter to the Editors

J Clin Psychopharmacol. 2016 Oct;36(5):522-3. doi: 10.1097/JCP.0000000000000567.
No abstract available

MeSH terms

  • Antimanic Agents
  • Bipolar Disorder
  • Humans
  • Lurasidone Hydrochloride*
  • Outpatients*
  • Treatment Outcome

Substances

  • Antimanic Agents
  • Lurasidone Hydrochloride